Investigational Drug Information for Lorecivivint
✉ Email this page to a colleague
What is the drug development status for Lorecivivint?
Lorecivivint is an investigational drug.
There have been 7 clinical trials for Lorecivivint.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 26th 2020.
The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and [disabled in preview]. The leading clinical trial sponsors are Biosplice Therapeutics, Inc., Samumed LLC, and [disabled in preview].
There are ten US patents protecting this investigational drug and ninety-nine international patents.
Summary for Lorecivivint
| US Patents | 10 |
| International Patents | 99 |
| US Patent Applications | 37 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2020-05-26) |
| Vendors | 41 |
Recent Clinical Trials for Lorecivivint
| Title | Sponsor | Phase |
|---|---|---|
| A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) | Biosplice Therapeutics, Inc. | Phase 3 |
| 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee | Biosplice Therapeutics, Inc. | Phase 3 |
| Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers | Biosplice Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for Lorecivivint
Top disease conditions for Lorecivivint
Top clinical trial sponsors for Lorecivivint
US Patents for Lorecivivint
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lorecivivint | ⤷ Try a Trial | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| Lorecivivint | ⤷ Try a Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| Lorecivivint | ⤷ Try a Trial | Treatment of osteoarthritis | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| Lorecivivint | ⤷ Try a Trial | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-y- l)pyridin-3-yl)-3-methylbutanamide | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| Lorecivivint | ⤷ Try a Trial | Single-dose, ready-to-use injectable formulations | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| Lorecivivint | ⤷ Try a Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lorecivivint
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lorecivivint | Australia | AU2017274350 | 2036-06-01 | ⤷ Try a Trial |
| Lorecivivint | Brazil | BR112018074725 | 2036-06-01 | ⤷ Try a Trial |
| Lorecivivint | Canada | CA3026076 | 2036-06-01 | ⤷ Try a Trial |
| Lorecivivint | Chile | CL2018003423 | 2036-06-01 | ⤷ Try a Trial |
| Lorecivivint | Chile | CL2021000611 | 2036-06-01 | ⤷ Try a Trial |
| Lorecivivint | China | CN109476660 | 2036-06-01 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
